ACCESS PHARMACEUTICL (ACCP)

3.12
0.08 2.50
NASDAQ
Prev Close 3.20
Open 3.16
Day Low/High 3.10 / 3.20
52 Wk Low/High 2.88 / 30.00
Volume 6.23K
Exchange NASDAQ
Shares Outstanding 26.70M
Market Cap 6.54M
Div & Yield N.A. (N.A)

Latest News

Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance For ProctiGard™

Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance For ProctiGard™

New product offers treatment to significant unmet medical need in supportive cancer care

Access Pharmaceuticals Awarded Hong Kong Patent For MuGard

Access Pharmaceuticals Awarded Hong Kong Patent For MuGard

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets

Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox

Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of Amlexanox

Additional Mucoadhesive Polymer Hydrogel Technology Formulation; Seeking Marketing Partners

Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology

Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners

Access Pharmaceuticals Cobraxane™ Offers Enhanced Tumor Growth Inhibition In Tumor Models

Access Pharmaceuticals Cobraxane™ Offers Enhanced Tumor Growth Inhibition In Tumor Models

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology

Access Pharmaceuticals Advances Development Of ProctiGard™ For Radiation Proctitis

Access Pharmaceuticals Advances Development Of ProctiGard™ For Radiation Proctitis

Leveraging Proprietary Mucoadhesive Polymer Hydrogel Technology to Expand Product Offerings; Seeking Global Marketing Partners

Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal

Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal

Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score

Access Pharmaceuticals Awarded Second European Patent For MuGard

Access Pharmaceuticals Awarded Second European Patent For MuGard

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets

Access Pharmaceuticals Announces Positive Top-Line Data From MuGard™ Phase IV Clinical Trial In Oral Mucositis Patients Presented At MASCC/ISOO 2013 Symposium

Access Pharmaceuticals Announces Positive Top-Line Data From MuGard™ Phase IV Clinical Trial In Oral Mucositis Patients Presented At MASCC/ISOO 2013 Symposium

Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score

Access Pharmaceuticals Reports First Quarter Results

Access Pharmaceuticals Reports First Quarter Results

MuGard Gross Revenues Up 118% Quarter-on-Quarter and Over 20% from Q4 2012

Rush University Medical Center Presents Positive MuGard Clinical Data At The Oncology Nursing Society 38th Annual Congress

Rush University Medical Center Presents Positive MuGard Clinical Data At The Oncology Nursing Society 38th Annual Congress

128 Patient MuGard Study Underscores the Powerful Clinical Impact MuGard Provides Cancer Patients Suffering with Oral Mucositis

Access Pharmaceuticals To Host Fourth Quarter And Fiscal Year Investor Call On Wednesday, April 3rd At 11:00am ET

Access Pharmaceuticals To Host Fourth Quarter And Fiscal Year Investor Call On Wednesday, April 3rd At 11:00am ET

MuGard Gross Revenues up 586% year-on-year, and 256% quarter-on-quarter

Access Pharmaceuticals To Host Third Quarter Investor Call On Wednesday, November 28th

Access Pharmaceuticals To Host Third Quarter Investor Call On Wednesday, November 28th

Company Schedules Conference Call Wednesday, November 28th at 11:00AM ET to Update Investors on MuGard Commercial Activities

Access Pharmaceuticals Announces Private Placement Financing

Access Pharmaceuticals Announces Private Placement Financing

Company financing includes $4.7 million of new investment and the exchange of approximately $5.3 million of outstanding dividends payable

Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium

Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium

MuGard Demonstrates Statistically Significant Reduction in Pain Associated With Oral Mucositis, Delay to Onset of Oral Mucositis, and Reductions In Weight Loss and the Use of Opioid Pain Medication